VEGFA and neoplasm: We previously found that anti-VEGF therapy increases the invasive characteristics of GSC11 cells in vivo [9]; that is, tumor cells that develop bevacizumab resistance become more aggressive and more invasive in the setting of continuous bevacizumab treatment.